Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Shirish M. Gadgeel is a leading thoracic oncologist whose research has profoundly shaped the treatment of lung cancer, particularly through the development of targeted therapies and immunotherapies. His seminal work on EGFR-mutant non-small cell lung cancer (NSCLC) helped establish the role of tyrosine kinase inhibitors, including osimertinib, as frontline standards of care. Dr. Gadgeel has also been instrumental in advancing immunotherapy combinations, such as pembrolizumab with chemotherapy, which have significantly improved survival outcomes for patients with advanced NSCLC. His contributions are widely recognized, with his most-cited papers collectively garnering thousands of citations—including a landmark trial on pembrolizumab in first-line NSCLC that alone has been cited over 1,500 times. Beyond his clinical research, Dr. Gadgeel has authored the *Handbook of Lung Cancer and Other Thoracic Malignancies*, a key resource for practitioners. He serves as a professor at the University of Michigan and holds leadership roles in national oncology committees, driving innovation in precision medicine and immunotherapy. His work continues to bridge the gap between laboratory discoveries and life-saving treatments for patients worldwide.